Median Technologies Has Been Confirmed as a Preferred Vendor by one of the Top 3 Pharmaceutical Companies in the World, and Selected to Implement Their Clinical Trial Imaging Strategy on Some Key Oncology Indications
- This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company.
- The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years.
- This partnership will contribute to sustain Median’s future bookings and revenues growth.
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:
MEDIAN Technologies (Paris:ALMDT) (ALMDT:PA) announced today that the company has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world and selected to implement their clinical trial imaging strategy on some key oncology indications. As part of the confidentiality agreement, Median Technologies cannot disclose the name of the client nor the terms of the agreement.
The goal for this large pharmaceutical company is to improve operational execution, garnering faster results with a leaner methodology. Median will deliver imaging services for a portion of the client’s oncology Phase III trials.
The award came after an intensive bidding process and the renegotiation of the terms of the MSA with this client who has one of the largest pipelines in oncology. It is a recognition of Median’s performance, quality, and competitiveness for imaging services.
“We started to develop a relationship with this major pharmaceutical company several years ago, adapting our imaging workflow and technology to their specific needs while satisfying stringent processes to meet their quality standards. We are very pleased with this demonstration of trust, that takes our relationship to an entirely different level”, highlights Nicolas Dano, COO of the iCRO Business Unit at Median. “This partnership will contribute to sustain our future bookings and revenue growth, and we plan to replicate similar deals with other pharmaceutical companies”, he adds.
“We are thrilled to strengthen our collaboration with this major pharma client and to contribute, more than ever, to the industry effort to develop new oncology drugs that will save patients’ lives. An important differentiating factor was also our clinical, scientific, and artificial intelligence expertise”, adds Fredrik Brag, CEO and founder of Median Technologies.
About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on the Euronext Growth market. FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com
Head of Corporate and Marketing Communications
+33 6 10 93 58 88
Press - ALIZE RP
+33 6 64 18 99 59
Investors - ACTIFIN
+33 1 56 88 11 11
Source: Median Technologies